Login
Cart
Support
Search
Search
Search
Dave Jones
Appearances
View Grid
METABOLIC OUTCOMES AND KEY EFFICACY DATA FROM A PHASE 2 TRIAL EVALUATING COMBINATION OBETICHOLIC ACID AND BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
Date
May 18, 2024
INTRODUCTION: Obeticholic acid (OCA), a potent farnesoid X receptor agonist, is indicated as a second-line treatment for patients (pts) with primary biliary cholangitis (PBC) who have an inadequate response or intolerance to ursodeoxycholic acid…
Presenter
Alan Bonder
Speakers
Dave Jones
Cynthia Levy
University of Miami
Heng Zou
Antonio Civitarese
Frederik Nevens